Accurately diagnosing prostate cancer remains a significant challenge in men's health. Researchers at the University of Florida (UF) believe a new urine-based test could eventually provide clinical laboratories with a faster, more accurate way to distinguish aggressive disease from common benign prostate disorders.
In a study published in Analytical Chemistry, investigators at the UF Health Cancer Institute described a paper spray mass spectrometry technique that analyzes urine samples in less than 30 seconds. Rather than relying solely on prostate-specific antigen (PSA) blood testing—which is known to produce false positives and false negatives—the method identifies metabolic biomarkers associated with prostate cancer and other prostate conditions.
For clinical laboratories, the research highlights the growing role of metabolomics and mass spectrometry in cancer diagnostics. If validated in larger studies, the approach could reduce unnecessary biopsies and overtreatment while helping physicians make more informed decisions about patient management.
“We need new screening technologies that can guide fast, efficient, patient-friendly and safe diagnosis and treatment options to manage aggressive disease,” said Timothy Garrett, PhD, associate professor and chief of experimental pathology in the University of Florida Department of Pathology, Immunology and Laboratory Medicine and the study's senior author.
Mass spectrometry offers new diagnostic possibilities
The technique uses a small urine sample applied to triangular paper, where an electric current creates a spray that ionizes metabolites. A mass spectrometer then identifies patterns associated with prostate cancer, benign prostatic enlargement, or prostatitis.
Unlike some existing urine-based prostate tests, the method does not require a digital rectal exam before sample collection, potentially simplifying specimen collection while improving patient acceptance.
Researchers evaluated urine samples from 40 participants, including healthy individuals and patients with enlarged prostate, prostatitis, or prostate cancer. The analysis identified 37 significant metabolic features that differentiated the groups, demonstrating strong predictive accuracy in this early pilot study.
Garrett said the findings suggest the test can clearly distinguish prostate cancer from other prostate disorders while providing results in under 30 seconds.
For laboratory professionals, the study reflects broader efforts to move beyond PSA-only screening by incorporating multiplex biomarker analysis into prostate cancer diagnostics.
Although the findings require validation in much larger patient populations before clinical adoption, the technology illustrates how rapid mass spectrometry workflows continue to evolve in the clinical lab setting.
The UF team plans to expand testing in larger studies and ultimately develop an at-home urine collection approach that could make prostate cancer screening more accessible while preserving laboratory-based analytical testing. Clinical laboratory professionals should keep an eye on emerging technologies like this, as next-generation urine biomarker testing could eventually complement or improve upon today's prostate cancer screening workflow.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
